drugset / Trial / NCT02935010

Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment

NCT02935010

Phase 4 Completed 382 enrolled Shanghai Jiao Tong University School of Medicine
RandomizedParallel-groupSingle-blindTreatment

Summary

With markedly increased antibiotic resistance and unsatisfactory efficacies of common empiric eradication regimens in the mainland of China, tailored therapy may be the best choice to achieve good efficacy. This study compared the eradication rates, safety, and compliance of antibiotic sensitivity-based tailored therapy compared with empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.

Timeline

Start
2017-02-05
Primary completion
2018-03-31
Completion
2018-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg
Subject Bismuth Potassium Citrate Unknown 600 mg
Subject Clarithromycin Small molecule
Subject Esomeprazole Small molecule 20 mg
Subject Levofloxacin Small molecule
Subject Metronidazole Small molecule 400 mg